Skip to main content
. 2021 Aug 6;80(10):1322–1329. doi: 10.1136/annrheumdis-2021-220626

Table 2.

Patient characteristics by T-cell responses in those with no evidence of previous natural infection

Characteristics First dose (n=50) Second dose (n=46)
n No T-cell response T-cell response P value n No T-cell response T-cell response P value
n=37 (74.0%) n=13 (26.0%) n=8 (17.4%) n=38 (82.6%)
Gender Male 31 24 (77.4) 7 (22.5) 27 3 (11.1) 24 (88.9)
Female 19 13 (68.4) 6 (31.6) 19 5 (26.3) 14 (73.7)
Age Years (IQR) 54.9 (42.7–63.9) 49.4 (39.8–62.8) 65.1 (61.4–70.0) 51.9 (42.1–75.3) 0.02
Ethnicity White 28 20 (71.4) 8 (28.6) 24 4 (16.7) 20 (83.3)
Black 1 1 (100) 0 2 0 2 (100)
South Asian 19 15 (78.9) 4 (21.1) 18 4 (22.2) 14 (77.8)
Mixed-race 2 1 (50.0) 1 (50.0) 1 0 1 (100)
Other 0 0 0 1 0 1 (100)
Diagnosis AAV and anti-GBM disease 24 14 (58.3) 10 (41.7) 19 4 (21.1) 15 (78.9)
Podocytopathy* 15 13 (86.7) 2 (13.3) 15 2 (13.3) 13 (86.7)
Membranous GN 10 9 (90.0) 1 (10.0) 9 2 (22.2) 7 (77.8)
SLE 0 0 0 2 0 2 (100)
Other† 1 1 (100) 0 1 0 1 (100)
Comorbidities Diabetes 10 7 (70.0) 3 (30.0) 8 3 (37.5) 5 (62.5)
Asthma/COPD 10 7 (70.0) 3 (30.0) 11 2 (18.2) 9 (81.8)
Previous malignancy 0 0 0 0 0 0
Immunotherapy Rituximab 44 31 (70.5) 13 (29.5) 41 7 (17.1) 34 (82.9)
Last 6 months 32 21 (65.6) 11 (34.4) 28 4 (14.3) 24 (85.7)
Tacrolimus 11 11 (100) 0 0.04 12 3 (25.0) 9 (75.0)
Azathioprine 4 2 (50.0) 2 (50.0) 3 0 3 (100)
MMF 5 3 (60.0) 2 (40.0) 4 1 (25.0) 3 (75.0)
Methotrexate 0 0 0 1 1 (100) 0
Prednisolone 17 14 (82.3) 3 (17.6) 14 2 (14.3) 12 (85.7)
≥10 mg 5 4 (80.0) 1 (20.0) 3 1 (33.3) 2 (66.7)
Belimumab 0 0 0 0 0 0
No IS 1 1 (100) 0 1 0 1 (100)
Previous CYP 25 15 (60.0) 10 (40.0) 20 3 (15.0) 17 (85.0)
Vaccine AZ/ChAdOx1 22 13 (59.1) 9 (40.9) 0.05 17 1 (5.9) 16 (94.1)
Pfizer/ BNT162b2 28 24 (85.7) 4 (14.3) 29 7 (24.1) 22 (75.9)
Clinical parameter B-cell depletion 33 22 (66.7) 11 (33.3) 30 5 (16.7) 25 (83.3)
Hypogammaglobulinaemia 13 10 (76.9) 3 (13.1) 9 3 (33.3) 6 (66.7)

*Podocytopathy included minimal change disease and focal segmental glomerulosclerosis.

†Other diagnoses included C3 glomerulopathy and IgG4-related disease. Comparison between groups by χ2 test.

AAV, ANCA-associated vasculitis; COPD, chronic obstructive pulmonary disease; CYP, cyclophosphamide; GBM, glomerular basement membrane; GN, glomerulonephritis; IS, immunosuppression; MMF, mycophenolate mofetil; SLE, systemic lupus erythematosus.